Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative IMRT with concurrent capecitabine for locally advanced mid-low rectal cancer
ChiCTR-TNC-10001094Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- May 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Toxicity during chemoradiation, Postoperative complications and 1 more. Started May 2007; status: recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR-TNC-10001094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10001094.